Tenofovir (TFV) IVR

ApprovedSmall molecule

Gilead

Tenofovir (TFV) IVR is one of 357 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

126

Total Trials

Active Trials

356

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

Hepatitis B Virus InfectionActive, not recruiting

LymphomaActive, not recruiting

Acute-on-Chronic Liver FailureActive, not recruiting

Chronic HepatitisActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

FibrosisActive, not recruiting

Chronic Liver FailureActive, not recruiting

ImmunodeficiencyActive, not recruiting

Liver DiseaseActive, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Hepatitis B Virus InfectionPhase 3

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Acute-on-Chronic Liver FailurePreclinical

Active, not recruiting

Chronic HepatitisApproved

Active, not recruiting

Chronic Hepatitis B Virus InfectionPhase 2

Active, not recruiting

FibrosisPreclinical

Active, not recruiting

Chronic Liver FailureApproved

Active, not recruiting

ImmunodeficiencyPhase 2

Active, not recruiting

Liver DiseasePhase 2

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Tenofovir (TFV) IVR

Gilead

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Chronic Hepatitis

NCT06150014

Q4 2026

Phase 3Active, not recruiting

Hepatitis B

NCT04704024

Q3 2028

Recruiting

Hepatitis B

NCT06586983

Clinical

Trials by Indication[1]

Chronic Hepatitis29 trials

Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)

Completed· GSK logo

GSK·Phase 3·NCT01300234·512 enrolled

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

Completed· Gilead logo

Gilead·Phase 1·NCT01671787·51 enrolled

Roll-over After 3-year Trial for Tenofovir in Mild Chronic Hepatitis B

Unknown status·—·Phase 4·NCT02463019·160 enrolled

Show 26 more trials

Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study

Completed· GSK logo

GSK·Phase 4·NCT02195518·213 enrolled

Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT01491295·160 enrolled

Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection

Completed· Gilead logo

Gilead·Phase 3·NCT00734162·106 enrolled

Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

Completed· Novartis logo

Novartis·Phase 4·NCT01379508·241 enrolled

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

Terminated· Gilead logo

Gilead··NCT02258581·241 enrolled

Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.

Completed·YYoung-Suk Lim·Phase 4·NCT03241641·174 enrolled

Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B

Completed·MMyeong Jun Song··NCT02533544·572 enrolled

Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT04195074·300 enrolled

A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B

Completed·SSamjin Pharmaceutical Co., Ltd.·Phase 4·NCT05282407·118 enrolled

Use of TDF in Patients With Inactive Chronic Hepatitis B Infection

Completed·UUniversity Health Network, Toronto·Phase 3·NCT02600117·50 enrolled

Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum

Completed·MMylan (Taiwan) Ltd·Phase 4·NCT05355467·40 enrolled

Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B

Completed·SSamjin Pharmaceutical Co., Ltd.·Phase 4·NCT05286346·113 enrolled

A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B

Unknown status·TTongji Hospital·Phase 4·NCT03357822·2,000 enrolled

Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B

Completed·AAssembly Biosciences·Phase 1/2·NCT03109730·38 enrolled

A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir

Completed·—·N/A·NCT01918631·36 enrolled

Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir

Unknown status·UUijeongbu St. Mary Hospital·Phase 3·NCT03236584·76 enrolled

Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis

Completed· GSK logo

GSK·Phase 4·NCT02224456·197 enrolled

Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment

Completed· Gilead logo

Gilead·Phase 2·NCT02174276·195 enrolled

Effect of Tenofovir (TDF) on Renal Function in Patients With Chronic Hepatitis B

Not yet recruiting·—··NCT06896630·172 enrolled

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Completed·AAssembly Biosciences·Phase 1·NCT02908191·86 enrolled

Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B

Completed·—··NCT06573190·70 enrolled

Evaluate the Efficacy and Safety to Tenofovir Disoproxil in Chronic Hepatitis B Patients

Completed· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 4·NCT03485534·189 enrolled

A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection

Completed· Gilead logo

Gilead·Phase 4·NCT00736190·90 enrolled

Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resistance

Unknown status·YYonsei University··NCT03566030·300 enrolled

A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

Active, not recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT06150014·88 enrolled

A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B

Completed· GSK logo

GSK·Phase 4·NCT03258710·75 enrolled

Tenofovir Disoproxil Fumarate20 trials

Pharmacokinetics of Two Formulation of Tenofovir Disoproxil Fumarate

Completed·YYung Shin Pharm. Ind. Co., Ltd.·Phase 4·NCT04671563·28 enrolled

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients

Unknown status· Gilead logo

Gilead·Phase 3·NCT00007436

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00076791·66 enrolled

Show 17 more trials

Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

Unknown status· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 4·NCT04202536·152 enrolled

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Terminated·AAlios Biopharma Inc.·Phase 1·NCT03032536·54 enrolled

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

Terminated·FFHI 360·Phase 2·NCT00122512·500 enrolled

Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers

Completed· Gilead logo

Gilead·Phase 4·NCT00648817·8 enrolled

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00109603·17 enrolled

Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00120471·122 enrolled

Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251145·49 enrolled

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Completed· Roche logo

Roche·Phase 1·NCT01592305·40 enrolled

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

Completed·CCenters for Disease Control and Prevention·Phase 2·NCT00131677·400 enrolled

Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations

Unknown status· Gilead logo

Gilead·N/A·NCT00011089

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01709084·426 enrolled

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Completed· Gilead logo

Gilead·Phase 3·NCT00112047·517 enrolled

Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients

Completed· Gilead logo

Gilead·Phase 3·NCT00002450·600 enrolled

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

Completed·FFHI 360·Phase 2·NCT00122486·1,200 enrolled

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide

Not yet recruiting·BBeijing Continent Pharmaceutical Co, Ltd.·Phase 1·NCT07295873·64 enrolled

Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease

Recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 1·NCT06356662·60 enrolled

Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs

Completed· Gilead logo

Gilead·N/A·NCT00016588

Hepatitis B13 trials

Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission

Unknown status·AANRS, Emerging Infectious Diseases·Phase 4·NCT02937779·933 enrolled

The Study of Short-range Antiviral Treatment During Pregnancy to Block Mother-to-child Transmission of Hepatitis B Virus and Withdrawal Time

Unknown status·—··NCT03209908·380 enrolled

Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus

Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 1/2·NCT02995005·98 enrolled

Show 10 more trials

Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia

Recruiting·OOslo University Hospital··NCT06586983·4,500 enrolled

Arresting Vertical Transmission of Hepatitis B Virus

Completed·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT03567382·179 enrolled

Tenofovir in Pregnancy to Prevent Mother to Child Transmission of Hepatitis B.

Completed·UUniversity of Oxford·Phase 2·NCT04114890·27 enrolled

A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00033163·90 enrolled

Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand

Completed·IInstitut de Recherche pour le Developpement·Phase 3·NCT01745822·654 enrolled

Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT04196998·150 enrolled

TDF Combined With LDT for the Treatment of HBeAg-positive Hepatitis B Patients With Poor Response to TDF for 12 Months

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University··NCT04650828·200 enrolled

A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

Unknown status·SSun Yat-sen University·Phase 3·NCT04392700·706 enrolled

Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT02510963·300 enrolled

A Phase III, Randomized, 2x2 Factorial Trial to Assess the Efficacy of Antiviral Therapy in Women and Infants in Reducing Vertical Transmission of Hepatitis B in Africa

Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 3·NCT04704024·450 enrolled

Tenofovir6 trials

Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.

Completed· Gilead logo

Gilead·Phase 2·NCT00270556·100 enrolled

Examining Hair to Determine Tenofovir Exposure

Completed·PPublic Health Foundation Enterprises, Inc.·Phase 1·NCT00903084·24 enrolled

'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT

Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02454764

Show 3 more trials

Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03670355·49 enrolled

The Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects

Unknown status·IInje University·Phase 1·NCT03070405·20 enrolled

Modifiers of Tenofovir in the Female Genital Tract

Completed·UUniversity of Minnesota··NCT03377608·50 enrolled

Effectiveness5 trials

Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00119379·50 enrolled

Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients

Completed· Gilead logo

Gilead·Phase 2·NCT00002415·175 enrolled

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00705679·5,029 enrolled

Show 2 more trials

The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients

Unknown status· Gilead logo

Gilead·Phase 1·NCT00002396·60 enrolled

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00050895·775 enrolled

34 more indications

HIV infection5 trials

A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection

Completed· Gilead logo

Gilead·N/A·NCT00002453·300 enrolled

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01040091·34 enrolled

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01505114·594 enrolled

Show 2 more trials

Dose Optimisation of Stavudine for the Treatment of HIV Infection

Completed·WWillem Daniel Francois Venter·Phase 3·NCT02670772·1,077 enrolled

Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis

Enrolling by invitation·HHospitales Universitarios Virgen del Rocío··NCT05492565·500 enrolled

Fibrosis4 trials

HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT04640129·336 enrolled

Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03919565·120 enrolled

Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03920605·100 enrolled

Show 1 more trial

Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03957629·186 enrolled

Treatment4 trials

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00896051·50 enrolled

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00051831·19 enrolled

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

Recruiting·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03920618·150 enrolled

Show 1 more trial

Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment

Terminated·NNew Discovery LLC··NCT01715987·48 enrolled

Drug3 trials

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

Completed·RRhonda Brand·Phase 1·NCT04302896·30 enrolled

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00074581·3,526 enrolled

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00102206·6 enrolled

HIV2 trials

Study of Anti-HIV Therapy Intensification

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00034086·22 enrolled

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00028366·56 enrolled

Women2 trials

PK of TAF and TDF for PrEP in Pregnant and Postpartum Women

Completed·UUniversity of California, Los Angeles·Phase 3·NCT04937881·39 enrolled

NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT00089505·745 enrolled

Prophylaxis2 trials

Botswana Tenofovir Oral HIV Prophylaxis Trial

Terminated·CCenters for Disease Control and Prevention·Phase 2/3·NCT00111150·1,200 enrolled

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples

Completed·UUniversity of Washington·Phase 3·NCT00557245·4,758 enrolled

Bone2 trials

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00729573·518 enrolled

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01400412·262 enrolled

Chronic Hepatitis B Virus Infection2 trials

The Incidence of Postpartum Hepatitis in Pregnant Women With Chronic Hepatitis B Virus Infection

Unknown status·—·N/A·NCT03214302·560 enrolled

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04129554·130 enrolled

Drug Resistance2 trials

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00046033·118 enrolled

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00027339·53 enrolled

Interaction1 trial

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Completed·RR-Pharm·Phase 1·NCT03537404·36 enrolled

Unknown status·SSamsung Medical Center·Phase 4·NCT02308319·124 enrolled

Liver Disease1 trial

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Completed· Gilead logo

Gilead·Phase 2·NCT00298363·112 enrolled

Hepatitis B Virus Infection1 trial

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

Terminated·SSWOG Cancer Research Network·Phase 3·NCT03887702·4 enrolled

Cohort Study1 trial

The Lighthouse Tenofovir Cohort Study

Unknown status·LLighthouse Trust··NCT02381275·1,500 enrolled

Pregnant Women1 trial

The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation

Completed·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT03468907·111 enrolled

ESS1 trial

Replicor Compassionate Access Program

No longer available·RReplicor Inc.··NCT05683548

Adult1 trial

Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·N/A·NCT00608569·529 enrolled

Pregnancy1 trial

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT01066858·1,765 enrolled

Chronic HBV Infection1 trial

Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Vertical Transmission

Unknown status·NNew Discovery LLC··NCT04237376·600 enrolled

Immunodeficiency1 trial

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00799864·54 enrolled

Children1 trial

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00260078·75 enrolled

PrEP1 trial

PrEP Among MSM and TG in Myanmar

Completed·MMyanmar Oxford Clinical Research Unit··NCT04781426·200 enrolled

Hepatitis C1 trial

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00100581·2 enrolled

Acceptability1 trial

Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00592124·168 enrolled

Infants1 trial

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana

Completed·—··NCT04862975·164 enrolled

Function1 trial

Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF

Completed·HHumanity and Health Research Centre·Phase 4·NCT03356834·575 enrolled

Trial1 trial

The COMBAT HBV Feasibility Trial

Completed·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT05705427·317 enrolled

Medication1 trial

Three Month Course of Anti-HIV Medications for People Recently Infected With HIV

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00087464

Chronic Liver Failure1 trial

Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure

Completed·GGovind Ballabh Pant Hospital·Phase 4·NCT01074645·27 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients

Completed·—·Phase 4·NCT00647244·40 enrolled

Unspecified2 trials

Optimization of Antiretroviral Therapy

Completed·SShanghai Public Health Clinical Center·Phase 4·NCT02935075·184 enrolled

A Single and Multiple Ascending Dose Study of JNJ-64457744

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05423106·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 126 trial records for Tenofovir (TFV) IVR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tenofovir (TFV) IVR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tenofovir (TFV) IVR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Gilead

Tenofovir (TFV) IVR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2028

Trials by Indication[1]

Chronic Hepatitis29 trials

Tenofovir Disoproxil Fumarate20 trials

Hepatitis B13 trials

Tenofovir6 trials

Effectiveness5 trials

HIV infection5 trials

Fibrosis4 trials

Treatment4 trials

Drug3 trials

HIV2 trials

Women2 trials

Prophylaxis2 trials

Bone2 trials

Chronic Hepatitis B Virus Infection2 trials

Drug Resistance2 trials

Interaction1 trial

Lymphoma1 trial

Acute-on-Chronic Liver Failure1 trial

Hepatocellular Carcinoma1 trial

Liver Disease1 trial

Hepatitis B Virus Infection1 trial

Cohort Study1 trial

Pregnant Women1 trial

ESS1 trial

Adult1 trial

Pregnancy1 trial

Chronic HBV Infection1 trial

Immunodeficiency1 trial

Children1 trial

PrEP1 trial

Hepatitis C1 trial

Acceptability1 trial

Infants1 trial

Function1 trial

Trial1 trial

Medication1 trial

Chronic Liver Failure1 trial

Efficacy and Safety1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News